T1	Participants 48 96	hormone-resistant metastatic prostate carcinoma.
T2	Participants 146 208	51 patients with stage D hormone-resistant prostatic carcinoma
T3	Participants 816 868	poor initial performance status or liver involvement
T4	Participants 1187 1220	essentially geriatric population.
